Product Search
We provide safer and differentiated healthcare products to customers
by combining medical technologies.
PRODUCT
LEVOMOS TAB. 2.5/40 mg
Print
product information
LEVOMOS TAB. 2.5/40 mg
| Classification | Ethical the Counter(ETC) |
|---|---|
| Major Ingredients | Olmesartan medoxomil, ss amlodipine (amlodipine) |
| Efficacy/Effectiveness | |
| Appearance | Light yellow circular film coating |
product information
Information
1. Ingredients and Content
- olmesartan medoxomil ---------------------------------- 40 mg
- S-amlodipine (amlodipine) ----------------------------- - 2.5 mg
- olmesartan medoxomil ---------------------------------- 40 mg
- S-amlodipine (amlodipine) ----------------------------- - 2.5 mg
Details
1. Warning
The administration of drugs directly acting on the renin-angiotensin system in pregnant women 2 and 3 can cause damage and death to the fetus and newborn. Therefore, if you are pregnant, you should stop taking this drug immediately. (See section on administration for pregnant women)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main component and dihydropyridine derivative of NSAID
2) Pregnant and lactating women
3) Patients with severe hepatic impairment
4) Patients with severe aortic stenosis
5) Patients with biliary obstruction
6) Patients with kidney dialysis (no experience)
7) Shock patients
Patients with diabetes and / or moderate to severe renal impairment (glomerular filtration rate <60 mL / min / 1.73 m2) who are taking aliskiren (see section on drug interactions)
9) It should not be given to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption because it contains lactose.
The administration of drugs directly acting on the renin-angiotensin system in pregnant women 2 and 3 can cause damage and death to the fetus and newborn. Therefore, if you are pregnant, you should stop taking this drug immediately. (See section on administration for pregnant women)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the main component and dihydropyridine derivative of NSAID
2) Pregnant and lactating women
3) Patients with severe hepatic impairment
4) Patients with severe aortic stenosis
5) Patients with biliary obstruction
6) Patients with kidney dialysis (no experience)
7) Shock patients
Patients with diabetes and / or moderate to severe renal impairment (glomerular filtration rate <60 mL / min / 1.73 m2) who are taking aliskiren (see section on drug interactions)
9) It should not be given to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption because it contains lactose.